{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T20:56:04Z","timestamp":1771016164968,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":508,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.cmi.2022.06.024","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T02:50:56Z","timestamp":1656989456000},"page":"1609-1614","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Immunogenicity and safety of the meningococcal B recombinant (4CMenB) vaccine in allogeneic hematopoietic cell transplantation recipients"],"prefix":"10.1016","volume":"28","author":[{"given":"Christine","family":"Robin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rabah","family":"Redjoul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aude","family":"Terrade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ala-Eddine","family":"Deghmane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludovic","family":"Cabanne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Cordonnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhamed-Kheir","family":"Taha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2022.06.024_bib1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/14760584.2019.1557520","article-title":"The Global Meningococcal Initiative meeting on prevention of meningococcal disease worldwide: epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations","volume":"18","author":"Acevedo","year":"2019","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.cmi.2022.06.024_bib3","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1080\/21645515.2020.1729030","article-title":"Recent changes of invasive meningococcal disease in France: arguments to revise the vaccination strategy in view of those of other countries","volume":"16","author":"Taha","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.cmi.2022.06.024_bib4","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/j.vaccine.2017.03.007","article-title":"The epidemiology of invasive meningococcal disease in EU\/EEA countries, 2004-2014","volume":"35","author":"Whittaker","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2022.06.024_bib5","first-page":"564","article-title":"Characteristics and changes in invasive meningococcal disease epidemiology in France, 2006-2015","volume":"74","author":"Parent du Chatelet","year":"2017","journal-title":"J\u00a0Infect"},{"key":"10.1016\/j.cmi.2022.06.024_bib6","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1080\/21645515.2020.1849518","article-title":"Risk factors for invasive meningococcal disease: a retrospective analysis of the French national public health insurance database","volume":"17","author":"Taha","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.cmi.2022.06.024_bib7","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1038\/bmt.2016.181","article-title":"Bacterial meningitis in hematopoietic stem cell transplant recipients: a population-based prospective study","volume":"51","author":"van Veen","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cmi.2022.06.024_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(18)30600-5","article-title":"Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Cordonnier","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2022.06.024_bib9","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2022.06.024_bib10","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/20477724.2021.1972663","article-title":"Evolving strategies for meningococcal vaccination in Europe: overview and key determinants for current and future considerations","volume":"116","author":"Martin\u00f3n-Torres","year":"2022","journal-title":"Pathog Glob Health"},{"key":"10.1016\/j.cmi.2022.06.024_bib11","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1086\/511641","article-title":"Revaccination with measles, tetanus, poliovirus, Haemophilus influenzae type B, meningococcus C, and pneumococcus vaccines in children after hematopoietic stem cell transplantation","volume":"44","author":"Patel","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2022.06.024_bib12","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.bbmt.2011.07.027","article-title":"Safety and immunogenicity of the tetravalent protein-conjugated meningococcal vaccine (MCV4) in recipients of related and unrelated allogeneic hematopoietic stem cell transplantation","volume":"18","author":"Mahler","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.cmi.2022.06.024_bib13","doi-asserted-by":"crossref","first-page":"B87","DOI":"10.1016\/j.vaccine.2012.01.033","article-title":"The new multicomponentvaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens","volume":"30","author":"Serruto","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2022.06.024_bib14","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1080\/21645515.2016.1241358","article-title":"Immunogenicity and safety among laboratory workers vaccinated with Bexsero(R) vaccine","volume":"13","author":"Hong","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.cmi.2022.06.024_bib15","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1473-3099(11)70027-5","article-title":"From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak","volume":"11","author":"Caron","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2022.06.024_bib16","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1080\/14760584.2021.1940144","article-title":"Correlates of protection for meningococcal surface protein vaccines: lessons from the past","volume":"21","author":"Findlow","year":"2022","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.cmi.2022.06.024_bib17","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1128\/CVI.00304-10","volume":"18","author":"Kimura","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.cmi.2022.06.024_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2021.2011652","article-title":"Postmarketing surveillance of adverse events following meningococcal B vaccination: data from Apulia Region, 2014-19","volume":"18","author":"Stefanizzi","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.cmi.2022.06.024_bib19","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/14760584.2019.1580579","article-title":"Optimizing the timing of 4CMenB vaccination in adolescents and young adults based on immune persistence and booster response data","volume":"18","author":"Watson","year":"2019","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.cmi.2022.06.024_bib20","series-title":"European medicine","article-title":"Summary of product characteristics","author":"Bexsero","year":"2013"},{"key":"10.1016\/j.cmi.2022.06.024_bib21","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2017-4250","article-title":"Meningococcal B vaccine immunogenicity in children with defects in complement and splenic function","volume":"142","author":"Martin\u00f3n-Torres","year":"2018","journal-title":"Pediatrics"},{"key":"10.1016\/j.cmi.2022.06.024_bib22","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.vaccine.2018.12.059","article-title":"Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine","volume":"37","author":"Nolan","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.cmi.2022.06.024_bib23","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1056\/NEJMoa1900236","article-title":"Meningococcal B vaccine and meningococcal carriage in adolescents in Australia","volume":"382","author":"Marshall","year":"2020","journal-title":"N\u00a0Engl J Med"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X2200338X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X2200338X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:33:37Z","timestamp":1761118417000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X2200338X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1198743X2200338X"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2022.06.024","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of the meningococcal B recombinant (4CMenB) vaccine in allogeneic hematopoietic cell transplantation recipients","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2022.06.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}